Nanomedicine revolutionizes epilepsy treatment: overcoming therapeutic hurdles with nanoscale solutions

doi:10.1080/17425247.2024.2360528

科研成果详情

题名	Nanomedicine revolutionizes epilepsy treatment: overcoming therapeutic hurdles with nanoscale solutions
作者	Li, Shize 1,2,3,4; Zhang, Wenhao2,3,4; Zhu, Yuhao1,2; Yao, Qing1,2; Chen, Ruijie1,2,4; Kou, Longfa1,2,4; Shi, Xulai1,2,3
发表日期	2024-05-29
发表期刊	EXPERT OPINION ON DRUG DELIVERY 影响因子和分区
语种	英语
原始文献类型	Review ; Early Access
关键词	Epilepsy antiseizure drugs nanomedicine polymeric nanoparticles lipid nanoparticles
其他关键词	SOLID LIPID NANOPARTICLES ; GAMMA-AMINOBUTYRIC-ACID ; VAGUS NERVE-STIMULATION ; BLOOD-BRAIN-BARRIER ; DRUG-DELIVERY ; ANTISEIZURE MEDICATIONS ; POLYMERIC NANOPARTICLES ; PLGA-NANOPARTICLES ; CONTROLLED-TRIAL ; KETOGENIC DIET
摘要	IntroductionEpilepsy, a prevalent neurodegenerative disorder, profoundly impacts the physical and mental well-being of millions globally. Historically, antiseizure drugs (ASDs) have been the primary treatment modality. However, despite the introduction of novel ASDs in recent decades, a significant proportion of patients still experiences uncontrolled seizures.Areas coveredThe rapid advancement of nanomedicine in recent years has enabled precise targeting of the brain, thereby enhancing therapeutic efficacy for brain diseases, including epilepsy.Expert opinionNanomedicine holds immense promise in epilepsy treatment, including but not limited to enhancing drug solubility and stability, improving drug across blood-brain barrier, overcoming resistance, and reducing side effects, potentially revolutionizing clinical management. This paper provides a comprehensive overview of current epilepsy treatment modalities and highlights recent advancements in nanomedicine-based drug delivery systems for epilepsy control. We discuss the diverse strategies used in developing novel nanotherapies, their mechanisms of action, and the potential advantages they offer compared to traditional treatment methods.
资助项目	Zhejiang Provincial Natural Science Foundation [LGF22H090038, LHDMY23H310002]; Zhejiang Medical and Health Science and Technology Program [2022RC206]; Wenzhou Municipal Science and Technology Bureau [ZY2019007]; Zhejiang Medical Doctor Association [YS2022-2-001]; Health innovation talents program (L Kou) from Health Commission of Zhejiang Province
出版者	TAYLOR & FRANCIS LTD
ISSN	1742-5247
EISSN	1744-7593
卷号	21 期号:5 页码:735-750
DOI	10.1080/17425247.2024.2360528
页数	16
WOS类目	Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:001232103400001
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
PubMed ID	38787859
SCOPUSEID	2-s2.0-85194586726
通讯作者地址	[Kou, Longfa;Shi, Xulai]Wenzhou Med Univ, Affiliated Hosp 2, Dept Pharm, Wenzhou Municipal Key Lab Pediat Pharm, Wenzhou, Peoples R China. ; [Kou, Longfa;Shi, Xulai]Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
Scopus学科分类	Pharmaceutical Science
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/214654
专题	附属第二医院第二临床医学院，附属第二医院、育英儿童医院附属第二医院_儿童神经科
通讯作者	Kou, Longfa; Shi, Xulai
作者单位	1.Wenzhou Med Univ, Affiliated Hosp 2, Dept Pharm, Wenzhou Municipal Key Lab Pediat Pharm, Wenzhou, Peoples R China; 2.Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China; 3.Wenzhou Med Univ, Affiliated Hosp 2, Dept Pediat Neurol, Wenzhou, Peoples R China; 4.Key Lab Struct Malformat Children Zhejiang Prov, Wenzhou, Peoples R China
第一作者单位	附属第二医院; 第二临床医学院，附属第二医院、育英儿童医院; 附属第二医院_儿童神经科
通讯作者单位	附属第二医院; 第二临床医学院，附属第二医院、育英儿童医院
第一作者的第一单位	附属第二医院
推荐引用方式 GB/T 7714	Li, Shize,Zhang, Wenhao,Zhu, Yuhao,et al. Nanomedicine revolutionizes epilepsy treatment: overcoming therapeutic hurdles with nanoscale solutions[J]. EXPERT OPINION ON DRUG DELIVERY,2024,21(5):735-750.
APA	Li, Shize., Zhang, Wenhao., Zhu, Yuhao., Yao, Qing., Chen, Ruijie., ... & Shi, Xulai. (2024). Nanomedicine revolutionizes epilepsy treatment: overcoming therapeutic hurdles with nanoscale solutions. EXPERT OPINION ON DRUG DELIVERY, 21(5), 735-750.
MLA	Li, Shize,et al."Nanomedicine revolutionizes epilepsy treatment: overcoming therapeutic hurdles with nanoscale solutions".EXPERT OPINION ON DRUG DELIVERY 21.5(2024):735-750.